- Switzerland
- /
- Life Sciences
- /
- SWX:TECN
Tecan Group Full Year 2022 Earnings: Revenues Beat Expectations, EPS Lags
Tecan Group (VTX:TECN) Full Year 2022 Results
Key Financial Results
- Revenue: CHF1.14b (up 21% from FY 2021).
- Net income: CHF121.1m (flat on FY 2021).
- Profit margin: 11% (down from 13% in FY 2021). The decrease in margin was driven by higher expenses.
- EPS: CHF9.53 (down from CHF9.95 in FY 2021).
All figures shown in the chart above are for the trailing 12 month (TTM) period
Tecan Group Revenues Beat Expectations, EPS Falls Short
Revenue exceeded analyst estimates by 1.8%. Earnings per share (EPS) missed analyst estimates by 9.0%.
Looking ahead, revenue is forecast to grow 5.8% p.a. on average during the next 3 years, compared to a 10% growth forecast for the Life Sciences industry in Switzerland.
Performance of the Swiss Life Sciences industry.
The company's shares are down 1.3% from a week ago.
Balance Sheet Analysis
While it's very important to consider the profit and loss statement, you can also learn a lot about a company by looking at its balance sheet. We've done some analysis and you can see our take on Tecan Group's balance sheet.
If you're looking to trade Tecan Group, open an account with the lowest-cost platform trusted by professionals, Interactive Brokers.
With clients in over 200 countries and territories, and access to 160 markets, IBKR lets you trade stocks, options, futures, forex, bonds and funds from a single integrated account.
Enjoy no hidden fees, no account minimums, and FX conversion rates as low as 0.03%, far better than what most brokers offer.
Sponsored ContentValuation is complex, but we're here to simplify it.
Discover if Tecan Group might be undervalued or overvalued with our detailed analysis, featuring fair value estimates, potential risks, dividends, insider trades, and its financial condition.
Access Free AnalysisHave feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
About SWX:TECN
Tecan Group
Provides laboratory instruments and solutions in biopharmaceuticals, forensics, and clinical diagnostics in Europe, North America, Asia, and internationally.
Excellent balance sheet average dividend payer.
Similar Companies
Market Insights
Community Narratives

